Home | Welcome to Contract Pharma   
Last Updated Saturday, May 30 2015


Expert's Opinion

Packaging Predictions for Pharma/Biopharma in 2015
Graham Reynolds, Vice President of Marketing & Innovation, West Pharmaceutical Services, Inc.
January 20, 2015
Growth of biologics impacts parameters for optimal drug delivery  Read More »
Gurpreet Sandhu, Reva Pharmaceuticals
June 18, 2014
Biosimilars face far more demanding clinical, market access, manufacturing and sales and marketing requirements, than small-molecule generics did.  Read More »
Fereshteh Barei, Dauphine University
June 18, 2014
Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing   Read More »
Girish Malhotra, President, EPCOT International
April 9, 2014
Will Sun’s latest acquisition, and India's first peer-to-peer pharma mega-buy, change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?  Read More »
Emil Ciurczak, Consultant, DoraMaxx Consulting
April 9, 2014
Pharmaceutical operations, of all kinds, are simply too complex to rely on univariate thinking  Read More »
Andrew Badrot, CMS Pharma
January 30, 2014
DSM & Patheon unlock value through a creative merger  Read More »
David Shoemaker, Ph.D., Senior Vice President, R&D, Rho
January 8, 2014
Policy precedes science  Read More »
Ken Phelps, President and CEO, Camargo Pharmaceutical Services
November 6, 2013
505(b)(2) can result in product approval with lower risk, reduced costs, and faster time to market  Read More »
Jeff Wilson and Dave Kerns, Key Corporate Services, LLC
August 2, 2013
Behavioral interviewing to match job and job-seeker  Read More »
Mike Rozembajgier, vice president of Recalls, Stericycle ExpertRECALL
June 3, 2013
Recall simulations prepare pharma companies for the real deal  Read More »
Jeffery R. Nelson, CEO, Nelson Laboratories
July 13, 2012
NRCM can increase knowledge and confidence and become part of the culture  Read More »
Edward S. Price, PCI Synthesis
July 10, 2012
What to look for, and why  Read More »
Edward S. Price, PCI Synthesis
May 30, 2012
Big Pharma and venture capital reshape the CMO/CRO markets  Read More »
Andrew Badrot
May 15, 2012
What does the Kensey Nash deal say about DSM's growth strategy?  Read More »
Andreas Scherer, Ph.D.
March 21, 2012
Holy Grail or Buying Time?  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On